(Q38066258)

28 August 2017

1 reference

title

Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine (English)

1 reference

Peer Carsten Tfelt-Hansen

28 August 2017

1 reference

1 reference

series ordinal

1

object named as

Peer Tfelt-Hansen

1 reference

28 August 2017

Anders Hougaard

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

10 December 2012

1 reference

Expert Opinion on Drug Metabolism & Toxicology

28 August 2017

published in

1 reference

28 August 2017

volume

9

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

91-103

1 reference

Epidemiology of headache in a general population--a prevalence study.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Cost of disorders of the brain in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Burden of migraine in the United States: disability and economic costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

The cost of headache disorders in Europe: the Eurolight project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Secular changes in health care utilization and work absence for migraine and tension-type headache: a population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

The discovery and development of the triptans, a major therapeutic breakthrough

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

What do patients with migraine want from acute migraine treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

What can be learned from the history of recurrence in migraine? A comment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Rapid oral transmucosal absorption of sumatriptan, and pharmacodynamics in acute migraine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Zelrix: a novel transdermal formulation of sumatriptan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

5-Hydroxytryptamine and its role in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Coronary side-effect potential of current and prospective antimigraine drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Origin of pain in migraine: evidence for peripheral sensitisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Acute migraine therapy: new drugs and new approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Evidence for a vascular factor in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Cluster headache--acute and prophylactic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Sumatriptan for the treatment of migraine attacks--a review of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Sumatriptan needle-free subcutaneous (Sumavel(®) DosePro™) approved for the acute treatment of migraine, with or without aura, and cluster headaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Sumatriptan and naproxen sodium for the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Sumatriptan-naproxen for acute treatment of migraine: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain--results of a model-based meta-analysis that accounts for encapsulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Unpublished clinical trials with sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Over-the-counter triptans for migraine : what are the implications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Increasing the effect of triptans in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

Comparison of the Efficacy of Zolmitriptan and Sumatriptan: Issues in Migraine Trial Design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.744394

10.1517/17425255.2013.744394

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference